News & Insights

• Orthox has announced the completion of a further £3.2m to close its £9.2m Series A financing round.
• Orthox is a clinical stage company developing medical implants to repair damaged knee articular cartilage and other orthopaedic injuries.
• The financing will support further clinical trials of its lead product, FibroFix™, at Southmead Hospital Bristol, UK and in Budapest, Hungary.

• Biofidelity has closed a £17.3m Series A+ funding round led by led by Octopus Ventures and SBI Investment Co Ltd.
• The capital will be used to commercialise Biofidelity’s ASPYRE technology, a high sensitivity molecular diagnostic platform and the first assay for high sensitivity diagnosis of non-small-cell-lung-cancer. This is will include launch in North America.
• The funding will also be used to expand and validate Biofidelity’s technology platform on other key oncology applications where access to high sensitivity precision diagnostics is key to improving outcomes.

• ONI has closed a $75m Series B financing led by US investors ARCH Venture Partners and Casdin Capital.
• ONI is a pioneer in observing single molecules in living cells. The Company’s first product, the Nanoimager, is the world’s first desktop, super-resolution, single-molecule imaging platform capable of visualising and tracking individual molecules in complex systems such as nanoparticles, living cells and tissue with 20nm resolution.
• The Series B funds will be used to build a product portfolio that harnesses the Company’s innovative technology to unlock new possibilities in therapeutic and diagnostic development, as well as basic life sciences research.

• OrganOx Ltd. is commercialising the metra L, the world’s first normothermic liver perfusion device.
• OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a £6.4 million round led by Oxford Investment Consultants LLP.
• Funding will accelerate a number of programmes in OrganOx’s R&D pipeline, with a Phase I clinical trial for a normothermic kidney perfusion device due to start later this year.
• This investment in OrganOx Ltd., brings the total funds invested by OTIF in the Company to £5.6m.

We recently held a webinar featuring presentations from Christoph Birkl (CEO) & Carolyn Hicks (CFO/COO) of portfolio company Brill Power, and Barnaby Balmforth, CEO of portfolio company Biofidelity.